Vaccinal strategy
US12144851B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Apr 12, 2019 |
| Grant date | Nov 19, 2024 |
| Priority date | — |
| Expiry date | May 5, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/876
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the prevention and treatment of disease like cancer. The inventors have previously characterized MELOE-1 antigen as an IRES dependent, melanoma specific translation product from a lncRNA mainly transcribed in the melanocytic lineage. MELOE-1 contains numerous class II epitopes and one HLA-A*0201-restricted CD8 epitope eliciting a frequent repertoire of high avidity T cells. They designed various synthetic long peptide (SLPs) comprising a CD4 epitope coupled to the CD8 epitope by a serie of linkers of 4 to 6 aa and studied the efficacy of T cell clone activation by SLP-loaded DC in vitro. Particularly, they evaluated the ability of a few selected SLPs to stimulate specific T cells proliferation of PBL from healthy donors in vitro and finally, they explored the vaccination potential of their best SLP candidate in vivo in an HLA*A0201/HLA-DRB0101 transgenic mouse. Thus, the present invention relates a SLP comprising a CD4 class II peptide linked to a CD8 class I peptide by a specific linker and its use in the treatment of disease like cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.